- Pharmaceutical Executive: March 2024
- Volume 44
- Issue 3
How’s Business?
The new season could bring with it more possibilities for renewal in the biotech sector, as our coverage this month highlights.
With Spring almost upon us, welcome to the March issue of Pharmaceutical Executive, which, in a way, delves into seasonal-type changes that have occurred for market sectors or are guiding new practices for various functions—and what may be next in approaching seasons.
Take, for example, the biotech sector, where we feature a few different perspectives on the state of affairs. Highlighting the coverage is the latest life sciences business pulse check from Peter Young, CEO of Young and Partners and a longtime Pharm Exec Editorial Advisory Board member. In his
Echoing similar sentiments is a
Not to be outdone on this front as well are a pair of columns in March—
Thanks for reading.
Articles in this issue
over 1 year ago
Pharmaceutical Executive: March 2024 Issue (PDF)over 1 year ago
Eyeing Efficiency for Allover 1 year ago
Straight and Simple Advice Lives On in the Pharma Industryover 1 year ago
A Return to the Fundamentals in Biotech Investment?over 1 year ago
The Shifting Landscape of the Life Sciences Job Marketover 1 year ago
Copay Adjustment Programs: What’s Next for Manufacturers?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.